Terapia genowa hemofilii – czy wkrótce będzie możliwe wyleczenie?

Haemophilia is a bleeding disorder (usually congenital) caused by the deficiency of coagulation factor VIII (haemophilia A) or IX (haemophilia B). The genes encoding factors VIII and IX are located on the X chromosome, so the symptoms of congenital haemophilia A and B occur predominantly in males. Recurring episodes of spontaneous bleeding into joints are the main symptom of haemophilia, which lead to haemophilic artropathy. Historically, patients with haemophilia were treated with whole blood transfusions and then with blood plasma. The first big breakthrough in treatment efficacy was the advent of cryoprecipitate, followed by lyophilized  coagulation factor concentrates, derived from plasma. The latter dramatically improved patients’ quality of life and allowed for prophylactic self-infusions at home (home treatment). Since the 1990s, the standard treatment has also included recombinant coagulation factor concentrates derived from cell cultures. Today, the main challenges are the need for frequent venipunctures (factor concentrates must be administered intravenously) to maintain successful prophylaxis and emergence of neutralizing antibodies in response to exogenous coagulation factors. Several novel recombinant factors with extended half-life were approved in recent years. Clinical  trials of other new technologies are ongoing. These are non-replacement therapies with different mechanisms of action (e.g. emicizumab, a bispecific antibody that mimics the procoagulant activity of factor VIII; fitusiran, siRNA downregulating antithrombin III) and gene therapies using AAV vectors.